Setipiprant/PGE2 feedbacks? 5/10/2018
The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Best, possible, or experimental growth agonists that AREN'T MINOXIDIL.
Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.
community Why not Travopost? More effective than min, and stackable.
Travoprost may be more effective than minoxidil for hair growth and can be used alongside it, but its effectiveness is debated due to inconsistent dosing results. Travoprost is expensive and not widely used, with alternatives like latanoprost and bimatoprost being more accessible.
community Anyone here has experience with ‘nuke’ protocols?
The conversation discusses aggressive hair loss treatments, including finasteride, dutasteride, minoxidil, topical cetirizine, and experimental options like Estrogel, oh-flutamide, and RU58841. Users share experiences and suggest trying oral minoxidil and el cranell, noting the complexity and challenges of treating hair loss.
community DLQ01: A Better "Minoxidil" PGF2a synthetic analogue.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
community Painkillers May Block Minoxidil
Painkillers like Aspirin may reduce Minoxidil's effectiveness by inhibiting the enzyme PGHS-1, which is crucial for hair growth. Using NSAIDs that inhibit COX-2 or combining Minoxidil with PGF2/E2 analogues or retinoids may enhance its efficacy.
Related Research
6 / 6 results
research Androgenetic Alopecia: An Update of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
research Experimental and early investigational drugs for androgenetic alopecia
This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.
research Treatments options for alopecia
This article discusses the social and psychological impact of hair disorders and the challenges in their treatment, but reports no new clinical results.
research Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation
This review highlights that recent advancements in diagnostics and therapies, including AI-enhanced imaging, biomarker analysis, and novel treatments like low-dose oral minoxidil and JAK inhibitors, are improving the precision and customization of hair loss management.
research A review of the treatment of male pattern hair loss
This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.
research Conventional and novel stem cell based therapies for androgenic alopecia
This review analyzes therapies used for androgenic alopecia, highlighting potential advances from stem cell technologies and regenerative medicine, and reports no new clinical results.